Dr Reddy’s Lab launches generic eye treatment medication in US
PTI, Jan 27, 2023, 5:13 PM IST
Representative Image (Source: Pexels)
New Delhi: Dr Reddy’s Laboratories on Friday said it has launched Difluprednate Ophthalmic Emulsion, used in the treatment of pain and swelling in the eyes caused by infection or allergy after eye surgery, in the American market.
The company has launched the medication, a generic version of Durezol (Difluprednate Ophthalmic Emulsion 0.05 per cent) in the US market, after getting approval from the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a statement.
As per IQVIA data, the Durezol brand and generics had sales of around USD 40 million in the US for the most recent twelve months ending in November 2022. Dr Reddy’s shares on Friday ended 2.78 percent up at Rs 4,321.35 apiece on the BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
RBI announces MPC schedule for FY25, first rates decision on April 5
Seven out of ten Indian shoppers say they would happily receive product deliveries without additional packaging
Renault Nissan to launch four new products, expand product portfolio
Sensex, Nifty rebound on heavy buying in Reliance Industries, HDFC Bank
IndiGo to fly more international routes, destinations; aims doubling size by 2030: CEO Pieter Elbers
MUST WATCH
Latest Additions
Rs 20.14 cr unaccounted cash seized in poll run up in Karnataka
HC grants bail to man held for sexually assaulting ‘friend’ at Mumbai beach in 2021
Congress’s Kolar conundrum remains unsolved despite CM, DCM attempt to quell dissent
Mangaluru: Illegal slaughterhouse raided by police, Three arrested
‘No evidence of wrongdoing’: CBI closes UPA-era Air India aircraft leasing